Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Takeda's MRs to Deal with All of Its Products: Mr Yamanaka
July 16, 2007
- Nippon Shinyaku to Rebuild Pipeline with Niche Products: New President Maekawa
July 16, 2007
- Adhesives Most Preferred Dosage Form of Narcotics for Cancer Pain
July 16, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 16, 2007
- Research to Prevent Progression of CKD to Dialysis to Start
July 16, 2007
- Expenditures under NHI Programs in 2006 Rose Only 0.5%
July 16, 2007
- R&D NEWS IN BRIEF
July 16, 2007
- Draft Guidance for MD Studies Presented
July 16, 2007
- 420 Generics Receive NHI Price Listing
July 16, 2007
- Astellas, Kyoto Univ. Start Collaborative Drug Discovery
July 16, 2007
- Differences in Opinion over Generics Sharpen between JMA and Bill Payers
July 9, 2007
- 27% Sales Growth for Philips Medical Systems in Japan in 2006: Dr Smit
July 9, 2007
- seminar／Generic Substitution Essential to Further Promote Use of Generics: Dr Masuhara
July 9, 2007
- Eisai Aims at 20% Increase in Sales of Actonel with Once-Weekly Formulation
July 9, 2007
- GENERICS NEWS IN BRIEF
July 9, 2007
- Yakult Licenses Anticancer Agent Satraplatin from GPC Biotech
July 9, 2007
- Cephalon to File NDA for Bendamustine in US: SymBio
July 9, 2007
- GSK Deploys 630 Specialist MRs to Promote Adoair
July 9, 2007
- Nat'l Centers Should Form Healthcare Clusters to Promote Clinical Research
July 9, 2007
- GSK to Launch 5 New Drugs for Cancer in Next 3 Years
July 9, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…